Hepatitis B Cure News at Karren Lemons blog

Hepatitis B Cure News. Gsk plc announced today that the us food and drug administration (fda) has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide (aso) for the treatment of chronic hepatitis b (chb). The new nih plan defines a hepatitis b “cure” as a sustained loss of a specific protein on the surface of hbv called hepatitis b virus surface antigen — preferably with antibodies against the antigen and undetectable viral dna after completion of a finite course of treatment. The biggest unmet need for hepatitis b patients is a cure, but there are a number of trials looking to achieve functional cure for the disease. Gsk’s bepirovirsen, which is looking for a functional cure, showed very promising results during a phase ii readout in june 2022 and has now initiated a phase iii trial due to end in 2025. Maintaining momentum in developing such strategies will require continued investment. Innovative curative strategies could reshape the treatment of chronic hepatitis b. A functional cure is said to have been achieved if a biomarker called hepatitis b surface antigen (hbsag) is cleared from the blood and remains undetectable after stopping all treatment. Italian researchers have developed a combination of a drug and an antibody that triggers specific immune cells to fight the hepatitis virus, preventing it from damaging.

A functional cure is said to have been achieved if a biomarker called hepatitis b surface antigen (hbsag) is cleared from the blood and remains undetectable after stopping all treatment. Italian researchers have developed a combination of a drug and an antibody that triggers specific immune cells to fight the hepatitis virus, preventing it from damaging. Maintaining momentum in developing such strategies will require continued investment. Gsk plc announced today that the us food and drug administration (fda) has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide (aso) for the treatment of chronic hepatitis b (chb). Gsk’s bepirovirsen, which is looking for a functional cure, showed very promising results during a phase ii readout in june 2022 and has now initiated a phase iii trial due to end in 2025. The new nih plan defines a hepatitis b “cure” as a sustained loss of a specific protein on the surface of hbv called hepatitis b virus surface antigen — preferably with antibodies against the antigen and undetectable viral dna after completion of a finite course of treatment. The biggest unmet need for hepatitis b patients is a cure, but there are a number of trials looking to achieve functional cure for the disease. Innovative curative strategies could reshape the treatment of chronic hepatitis b.

Frontiers Current treatment of chronic hepatitis B Clinical aspects and future directions

Hepatitis B Cure News Gsk’s bepirovirsen, which is looking for a functional cure, showed very promising results during a phase ii readout in june 2022 and has now initiated a phase iii trial due to end in 2025. Maintaining momentum in developing such strategies will require continued investment. The biggest unmet need for hepatitis b patients is a cure, but there are a number of trials looking to achieve functional cure for the disease. Italian researchers have developed a combination of a drug and an antibody that triggers specific immune cells to fight the hepatitis virus, preventing it from damaging. Gsk’s bepirovirsen, which is looking for a functional cure, showed very promising results during a phase ii readout in june 2022 and has now initiated a phase iii trial due to end in 2025. A functional cure is said to have been achieved if a biomarker called hepatitis b surface antigen (hbsag) is cleared from the blood and remains undetectable after stopping all treatment. The new nih plan defines a hepatitis b “cure” as a sustained loss of a specific protein on the surface of hbv called hepatitis b virus surface antigen — preferably with antibodies against the antigen and undetectable viral dna after completion of a finite course of treatment. Gsk plc announced today that the us food and drug administration (fda) has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide (aso) for the treatment of chronic hepatitis b (chb). Innovative curative strategies could reshape the treatment of chronic hepatitis b.